Tarsus Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
15440 Laguna Canyon Rd Ste 160, Irvine, ...Phone Number
(949) 418-1801Website
www.tarsusrx.comRevenue
$606.3 MillionStock Symbol
TARSIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
2
1
1
About Tarsus Pharmaceuticals
Founded in 2017, Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for a range of diseases. The company's lead product is a topical ophthalmic that targets an underlying cause of blepharitis. Tarsus is headquartered in Irvine, California.Explore more
Tarsus Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tarsus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Tarsus Pharmaceuticals
Funding: Get notified immidiatlly once Tarsus Pharmaceuticals has new funding data
Tarsus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Tarsus Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Tarsus Pharmaceuticals launches new products
Earning: See what the market has to say on Tarsus Pharmaceuticals recently announced quarterly report
Check if Tarsus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Tarsus Pharmaceuticals is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Tarsus Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Tarsus Pharmaceuticals
Compare insights from companies similar to Tarsus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tarsus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tarsus Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals financials insights
Gather financial insights about Tarsus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$60M
2022
Debt
$175M
Tarsus Pharmaceuticals Tech Stack
A closer look at the technologies used by Tarsus Pharmaceuticals
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Tarsus Pharmaceuticals is planning to move offices in October 2026. The move will impact approximately 50 employees at the existing office located at 17700 Laguna Canyon Rd, Irvine, CA.
Facilities Relocation/Expansion
Open Position
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Seeking Replacement
Promotion
Executive Move
Executive Moves, Promotion
Tarsus Pharmaceuticals News & Media
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
Generated second quarter 2026 XDEMVY® net product sales of $173.9 million, an increase of more than 69% year-over-yearTarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $125.0 million, before deducting placement agent fees and other private placement expenses.Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the largest inherited retinal diseases with no FDA-approved therapyTarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its second quarter 2026 financial results and provide a corporate update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tarsus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Founded in 2017, Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for a range of diseases. The company's lead product is a topical ophthalmic that targets an underlying cause of blepharitis. Tarsus is headquartered in Irvine, California.... Read More
